Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. Founded in 1973, Abingworth has a lengthy track record of building market leading companies, and was the original institutional investor in Solexa. The specialist team of over 20 professionals has a broad range of skills, including scientific and business expertise as well as investment banking, recruitment, and legal knowledge. These resources are made available to portfolio companies. Abingworth has funds under management of over $1.25 billion and offices in London, Menlo Park, and Boston.
Lightspeed Venture Partners is a leading global venture capital firm that manages over $2 billion of capital commitments. Over the past two decades, Lightspeed’s investment professionals have backed more than 150 companies, many of which have gone on to become leaders in their respective industries. Headquartered in Menlo Park, Lightspeed invests in the U.S. and internationally, with investment professionals and advisors located in Silicon Valley, China, India and Israel.
Mohr Davidow is a large venture capital firm headquartered in Menlo Park, CA, with investments in Life Sciences, CleanTech, and Information Technologies (including cloud computing). The Mohr Davidow team has worked with, been on the board or has advised some of the most ground-breaking technology companies in the world including: Adobe; Agilent; Akamai; Affymetrix; Amersham; Brocade; Cerent; Cisco; Dupont; Hewlett Packard; Incyte; Microsoft; Novell; Oracle; Qualcomm; Rambus; and Rosetta Inpharmatics.
Hermann Hauser, Ph.D., F.R.S.
Hermann Hauser, co-founder of Amadeus Capital Partners, has enjoyed a long and successful career as an entrepreneur and venture capitalist. Amadeaus was an early investor in Solexa and Dr. Hauser served on its Board through the acquisition of Illumina. In 2009, Dr. Hauser was the first non-employee sequenced by Illumina’s commercial genome sequencing service.
Mr. Dotzler is a venture capitalist with over 23 years of investing experience in the life sciences and related fields. In 2000, he was the co-founder of De Novo Ventures, where he is now Managing Director.